Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | PYPD PolyPid Ltd. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $5.27 -0.4% | $16.31 +6.3% |
| StockIQ Score | 67B- Moderate Risk: High | 42D Weak Risk: Medium |
| Technical | 71B | 36F |
| Fundamental | — | 35F |
| Growth | — | 50C- |
| Fair Value | — | 38F |
| News | 74B | 50C- |
| Quality | — | 50C- |
| Risk | 34F | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
PolyPid (PYPD) outperforms Ascentage Pharma (AAPG) in investor and technical strength, scoring 67 and 71 respectively, compared to AAPG’s 42 and 36. PYPD’s "MODERATE" rating also suggests better overall stability than AAPG’s "WEAK" rating. However, AAPG has no missing scores, while PYPD lacks fundamental, growth, and valuation data.
